Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.

Authors

Muthiah Vaduganathan¹, Orly Vardeny¹, Thomas Michel¹, John J V McMurray¹, Marc A Pfeffer¹, Scott D Solomon¹

Affiliation

¹ From the Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston (M.V., T.M., M.A.P., S.D.S.); the Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, and University of Minnesota, Minneapolis (O.V.); and the British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (J.J.V.M.).

No abstract available

MeSH terms

Angiotensin Receptor Antagonists / pharmacology
Angiotensin Receptor Antagonists / therapeutic use*
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors / pharmacology
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Betacoronavirus / metabolism*
COVID-19
Coronavirus Infections / complications
Coronavirus Infections / metabolism*
Down-Regulation
Humans
Hypertension / complications
Hypertension / drug therapy*
Pandemics
Peptidyl-Dipeptidase A / metabolism*
Pneumonia, Viral / complications
Pneumonia, Viral / metabolism*
Renal Insufficiency, Chronic / complications
Renal Insufficiency, Chronic / drug therapy
Renin-Angiotensin System / drug effects*
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2